8-K filing — Vivos Therapeutics, Inc. (VVOS)
Filed: 2026-10-01 AccNo: 0001493152-26-045193 Size: 216 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Vivos Therapeutics Announces 212% Rise YoY Over Most Recent Six-Week Period In Its New Obstructive Sleep Apnea Patient Referrals At Its Nevada Sleep & Airway Medicine Centers
Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Vivos Therapeutics shares are trading higher after the company announced the execution by management of a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026.
Vivos Therapeutics Announces Restructuring And Cost Reduction Plan With An Annual Savings Target Of $3.6M From Q4 2026
Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract
8-K/A filing — Vivos Therapeutics, Inc. (VVOS)
Filed: 2026-09-08 AccNo: 0001493152-26-041807 Size: 241 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits